Velcade in MALT Lymphoma Patients

Phase II Trial pf Bortezomib in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type

Bortezomib for treatment of disseminated MALT lymphoma or at relapse following HP -eradication,or chemotherapy or radiation.

The objectives of this study are to evaluate the effectivity and the safety of bortezomib in patients with disseminated MALT lymphoma or at relapse following HP-eradication, or chemotherapy or radiation.

It is a phase II prospective single arm study with a target sample of 16 patients. 1.5mg/m2 Bortezomib is given intravenously on day 1,4,8,11 every three week, for a maximum of 8cycles.

Inclusion Criteria:

• patients with histologically confirmed MALT lymphoma with measurable disease (stage I-IV)
• with first or greater relapse after HP-eradication, radiation or chemotherapy ,
• age > 18 years
• must be able to tolerate therapy and have adequate cardiac, renal and hepatic function
• ECOG status of <_ 2
• must be capable of understanding the purpose of the study and given written informed consent